TapewireFind a company

person · Reporting owner

Grossman Adam S

Disclosed activity across 1 company

Tapewire entity
59867
SEC CIK
0001542517

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADMA BIOLOGICS, INC.ADMA · Entity 4477Director · President and CEOMarch 16, 2026March 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date March 16, 2026 · Filed March 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,133,777 Reported balance After 2026-03-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-03-16 · Exercise / conversion · Acquired 15,000 · Balance 2,133,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Common StockSEC Table I · non-derivativeDirect2,118,777 Reported balance After 2026-03-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-03-16 · Sale · Disposed 15,000 · Balance 2,118,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

Common StockSEC Table I · non-derivativeDirect2,112,777 Reported balance After 2026-03-16 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-03-16 · Sale · Disposed 6,000 · Balance 2,112,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2034-02-26Direct690,950 Reported balance After 2026-03-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-03-16 · Exercise / conversion · Disposed 15,000 · Balance 690,950

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,143,426 Reported balance Holding disclosure · report date 2026-03-16 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 1,143,426

F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

Common StockSEC Table I · non-derivativeIndirectSee Footnote580,957 Reported balance Holding disclosure · report date 2026-03-16 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 580,957

F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 19, 2025 Filed Mar 22, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-009928 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 855,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
March 19, 2025 Filed Mar 22, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $18.92 $113,520.00
Disclosure

SEC source: 0001140361-25-009928 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,061,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,029,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 19, 2025 Filed Mar 22, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $18.92 $283,800.00
Disclosure

SEC source: 0001140361-25-009928 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,067,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
March 19, 2025 Filed Mar 22, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-009928 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,082,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 29,513 $17.02 $502,311.26
Disclosure

SEC source: 0001140361-25-007924 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,067,850

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F4 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,035,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 56,438 $16.91 $954,366.58
Disclosure

SEC source: 0001140361-25-007924 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,097,363

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 990,197 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 26, 2025 Filed Feb 28, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 54,867 $15.78 $865,801.26
Disclosure

SEC source: 0001140361-25-006386 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,153,801

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F4 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F6 · balance_after: (continued from footnote 5) and (v) 903,211 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 25, 2025 Filed Feb 28, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 18,018 $15.44 $278,197.92
Disclosure

SEC source: 0001140361-25-006386 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,208,668

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 818,646 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 19, 2025 Filed Feb 22, 2025 02:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 376,744 $0.00 Strike: $16.07 $0.00
Disclosure

SEC source: 0001140361-25-005534 · form4.xml · derivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,744

Underlying: Common Stock · 376,744 shares

Expires 2035-02-19

F7 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan.

Read SEC document
February 19, 2025 Filed Feb 22, 2025 02:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 252,022 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-005534 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,226,686

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) and (vi) 790,876 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 31, 2024 Filed Jan 4, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 14,343 $17.15 $245,982.45
Disclosure

SEC source: 0001140361-25-000270 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,974,664

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting; and (v) 790,876 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 02:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 48,967 $21.10 $1,033,203.70
Disclosure

SEC source: 0001140361-24-047701 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,989,007

F1 · shares: These shares represent restricted stock units ("RSUs") that were granted on September 29, 2021 and vested on June 30, 2024 and September 30, 2024.

F2 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.13. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes, as of the transaction date, (i) 557,728 restricted stock units ("RSUs") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 56,719 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) and (vi) 748,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 30, 2024 Filed Oct 3, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 21,752 $19.99 $434,822.48
Disclosure

SEC source: 0001140361-24-042641 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,037,974

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 557,728 restricted stock units ("RSUs") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 56,719 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) and (vi) 797,467 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 27, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 47,396 $2.92 Strike: $2.92 $138,159.34
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 18

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 47,396 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F13 · derivative.exercise_date: These options were granted on February 28, 2020 and vested over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.

Read SEC document
August 27, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 341,960 $3.35 Strike: $3.35 $1,145,566.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 17

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,020

Underlying: Common Stock · 341,960 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: These options were granted on March 6, 2023 and vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027.

Read SEC document
August 27, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 389,356 $17.29 $6,732,899.69
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 9

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,059,726

F2 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.375. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes, as of the transaction date, (i) 557,728 restricted stock units ("RSUs") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 113,438 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) and (vi) 762,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 27, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 47,396 $2.92 $138,159.34
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 8

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,449,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 27, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 341,960 $3.35 $1,145,566.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 7

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,401,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 60,000 $10.80 Strike: $10.80 $648,000.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 16

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2025-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date.

F12 · derivative.exercise_date: These options were granted on January 30, 2015 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on January 30, 2019.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 40,500 $9.37 Strike: $9.37 $379,485.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 15

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,500 shares

Expires 2025-10-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date.

F11 · derivative.exercise_date: These options were granted on October 9, 2015 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on October 9, 2019.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 16,984 $5.96 Strike: $5.96 $101,224.64
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 14

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,984 shares

Expires 2026-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date.

F10 · derivative.exercise_date: These options were granted on January 28, 2016 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on January 28, 2020.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 55,000 $5.00 Strike: $5.00 $275,000.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 13

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2027-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: These options were granted on February 14, 2017 and vested over four years with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 64,405 $3.35 Strike: $3.35 $215,756.75
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · derivative · entry 12

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,082,980

Underlying: Common Stock · 64,405 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: These options were granted on March 6, 2023 and vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 236,889 $17.69 $4,191,087.57
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,059,726

F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.45. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 60,000 $10.80 $648,000.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 5

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,296,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 40,500 $9.37 $379,485.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,236,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 16,984 $5.96 $101,224.64
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,196,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 55,000 $5.00 $275,000.00
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,179,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 26, 2024 Filed Aug 28, 2024 01:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 64,405 $3.35 $215,756.75
Disclosure

SEC source: 0001140361-24-038772 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,124,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 30, 2024 Filed Jul 3, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 21,752 $11.18 $243,187.36
Disclosure

SEC source: 0001140361-24-032245 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President,CEO, and Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,059,726

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 113,438 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) and (vi) 762,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
June 14, 2024 Filed Jun 15, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 100,000 $10.72 $1,071,980.00
Disclosure

SEC source: 0001140361-24-030232 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President,CEO, and Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,081,475

F7 · kind: These shares were sold by the reporting person in connection with the Divorce Settlement.

F3 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
June 14, 2024 Filed Jun 15, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-030232 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President,CEO, and Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,181,475

F6 · kind: The shares were transferred by the reporting person to a third party in connection with the Divorce Settlement.

F3 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
June 14, 2024 Filed Jun 15, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 OtherCommon Stock 460,000 $3.21 $1,476,600.00
Disclosure

SEC source: 0001140361-24-030232 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President,CEO, and Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,191,475

F1 · kind: The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement").

F2 · price: The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 31, 2024 Filed Apr 3, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 21,752 $6.60 $143,563.20
Disclosure

SEC source: 0001140361-24-017376 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President,CEO, and Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,651,475

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) and (vi) 1,297,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 07, 2024 Filed Mar 9, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 28,763 $6.16 $177,180.08
Disclosure

SEC source: 0001140361-24-012445 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,673,227

F1 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F2 · balance_after: (continued from footnote 2) (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 3) and (vi) 1,262,567 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 06, 2024 Filed Mar 9, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 55,003 $6.12 $336,618.36
Disclosure

SEC source: 0001140361-24-012445 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,701,990

F1 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F2 · balance_after: (continued from footnote 2) (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 3) and (vi) 1,262,567 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 29, 2024 Filed Mar 5, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 9,588 $5.36 $51,391.68
Disclosure

SEC source: 0001140361-24-011194 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,756,993

F1 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F2 · balance_after: (continued from footnote 1) (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) and (vi) 1,127,910 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 26, 2024 Filed Feb 29, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 870,950 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-24-010243 · form4.xml · derivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 870,950

Underlying: Common Stock · 870,950 shares

Expires 2034-02-26

F7 · derivative.exercise_date: The option vests over four years with 25% of the shares of Common Stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028 in accordance with the Plan.

Read SEC document
February 26, 2024 Filed Feb 29, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 557,728 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-010243 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,766,581

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each three-month anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into

F3 · balance_after: (continued from footnote 2) common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) and (vi) 1,137,498 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 25, 2024 Filed Feb 28, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 22,457 $5.26 $118,123.82
Disclosure

SEC source: 0001140361-24-009842 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,208,853

F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 45,785 unvested RSUs granted on February 25, 2021, of which 45,788 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,112,498 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 31, 2023 Filed Jan 6, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 23,057 $4.52 $104,217.64
Disclosure

SEC source: 0001140361-24-001138 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,231,310

F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,076,399 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 30, 2023 Filed Oct 4, 2023 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 18,718 $3.58 $67,010.44
Disclosure

SEC source: 0001140361-23-046743 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,254,367

F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 283,594 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,042,737 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 18, 2023 Filed Aug 19, 2023 01:46 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 250,000 $4.15 $1,038,350.00
Disclosure

SEC source: 0001140361-23-040583 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,273,085

F1 · price: Reflects the weighted average price of sales on August 18, 2023. The shares were sold in multiple transactions at prices ranging from $4.09 to $4.255, inclusive.

F2 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,004,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 16, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 3 $4.39 $13.16
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 9

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,523,085

F2 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 583,224 $3.66 Strike: $3.66 $2,134,599.84
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · derivative · entry 17

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 583,224 shares

Expires 2027-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 350,000 $3.71 Strike: $3.71 $1,298,500.00
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · derivative · entry 16

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 350,000 shares

Expires 2028-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 400,000 $3.22 Strike: $3.22 $1,288,000.00
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · derivative · entry 15

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 400,000 shares

Expires 2029-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 277,604 $2.92 Strike: $2.92 $809,215.66
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · derivative · entry 14

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,396

Underlying: Common Stock · 277,604 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 277,131 $2.35 Strike: $2.35 $651,257.85
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · derivative · entry 13

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,569

Underlying: Common Stock · 277,131 shares

Expires 2031-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 212,500 $1.67 Strike: $1.67 $354,875.00
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · derivative · entry 12

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 387,500

Underlying: Common Stock · 212,500 shares

Expires 2032-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.